BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Talsma DT, Poppelaars F, Dam W, Meter-Arkema AH, Vivès RR, Gál P, Boons GJ, Chopra P, Naggi A, Seelen MA, Berger SP, Daha MR, Stegeman CA, van den Born J; COMBAT Consortium. MASP-2 Is a Heparin-Binding Protease; Identification of Blocking Oligosaccharides. Front Immunol 2020;11:732. [PMID: 32425936 DOI: 10.3389/fimmu.2020.00732] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Milusev A, Rieben R, Sorvillo N. The Endothelial Glycocalyx: A Possible Therapeutic Target in Cardiovascular Disorders. Front Cardiovasc Med 2022;9:897087. [DOI: 10.3389/fcvm.2022.897087] [Reference Citation Analysis]
2 Vallet SD, Berthollier C, Ricard-Blum S. The glycosaminoglycan interactome 2.0. Am J Physiol Cell Physiol 2022. [PMID: 35544698 DOI: 10.1152/ajpcell.00095.2022] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Le Stang MB, Gleeson PJ, Daha MR, Monteiro RC, van Kooten C. Is complement the main accomplice in IgA nephropathy? From initial observations to potential complement-targeted therapies. Mol Immunol 2021;140:1-11. [PMID: 34601376 DOI: 10.1016/j.molimm.2021.09.010] [Reference Citation Analysis]